[go: up one dir, main page]

BRPI0318278B8 - Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro - Google Patents

Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro

Info

Publication number
BRPI0318278B8
BRPI0318278B8 BRPI0318278A BR0318278A BRPI0318278B8 BR PI0318278 B8 BRPI0318278 B8 BR PI0318278B8 BR PI0318278 A BRPI0318278 A BR PI0318278A BR 0318278 A BR0318278 A BR 0318278A BR PI0318278 B8 BRPI0318278 B8 BR PI0318278B8
Authority
BR
Brazil
Prior art keywords
compounds
composition
aminocyclohexyl ether
ion channel
channel activity
Prior art date
Application number
BRPI0318278A
Other languages
English (en)
Other versions
BR0318278A (pt
BRPI0318278B1 (pt
Inventor
Alexander Zolotoy
G M Barrett Anthony
Bertrand Plouvier
Ta Hung Chou Doug
Grace Jung
N Beatch Gregory
Jeff Zhu
Siu Leung Choi Lewis
J A Walker Michael
Richard Wall
L Yong Sandro
Tao Sheng
Yuzhong Liu
Original Assignee
Cardiome Pharma Corp
Correvio Canada Corp
Correvio Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp, Correvio Canada Corp, Correvio Int Sarl filed Critical Cardiome Pharma Corp
Publication of BR0318278A publication Critical patent/BR0318278A/pt
Publication of BRPI0318278B1 publication Critical patent/BRPI0318278B1/pt
Publication of BRPI0318278B8 publication Critical patent/BRPI0318278B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

compostos de éter aminocicloexílico e usos dos mesmos. são divulgados compostos de éter aminocicloexílico. os compostos da presente invenção podem ser incorporados em composições e kits. a presente invenção também divulga os usos para os compostos e as composições, incluindo o tratamento de arritmia.
BRPI0318278A 2003-05-02 2003-10-31 Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro BRPI0318278B8 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US46715903P 2003-05-02 2003-05-02
US47608303P 2003-06-04 2003-06-04
US47644703P 2003-06-05 2003-06-05
US47588403P 2003-06-05 2003-06-05
US47591203P 2003-06-05 2003-06-05
US48965903P 2003-07-23 2003-07-23
US49339203P 2003-08-07 2003-08-07
PCT/US2003/034655 WO2004099137A1 (en) 2003-05-02 2003-10-31 Aminocyclohexyl ether compounds and uses thereof

Publications (3)

Publication Number Publication Date
BR0318278A BR0318278A (pt) 2006-05-23
BRPI0318278B1 BRPI0318278B1 (pt) 2018-11-06
BRPI0318278B8 true BRPI0318278B8 (pt) 2024-01-09

Family

ID=33437310

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0318278A BRPI0318278B8 (pt) 2003-05-02 2003-10-31 Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
BR122018009866A BR122018009866B8 (pt) 2003-05-02 2003-10-31 métodos para preparar compostos de éter aminocicloexílico e compostos intermediários

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018009866A BR122018009866B8 (pt) 2003-05-02 2003-10-31 métodos para preparar compostos de éter aminocicloexílico e compostos intermediários

Country Status (21)

Country Link
US (3) US20070099983A1 (pt)
EP (3) EP2298735A1 (pt)
JP (2) JP4919661B2 (pt)
KR (1) KR101059379B1 (pt)
AT (2) ATE325789T1 (pt)
AU (2) AU2003287378B2 (pt)
BR (2) BRPI0318278B8 (pt)
CA (1) CA2524323C (pt)
CY (1) CY1105137T1 (pt)
DE (1) DE60305200T2 (pt)
DK (1) DK1560812T3 (pt)
ES (2) ES2375820T3 (pt)
IL (2) IL171653A (pt)
NO (1) NO334094B1 (pt)
NZ (1) NZ543921A (pt)
PL (1) PL227937B1 (pt)
PT (1) PT1560812E (pt)
RU (1) RU2478617C2 (pt)
SG (2) SG2010079697A (pt)
SI (1) SI1560812T1 (pt)
WO (1) WO2004099137A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4334766B2 (ja) 1998-04-01 2009-09-30 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物およびその用途
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
SG2010079697A (en) * 2003-05-02 2016-09-29 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7705036B2 (en) 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
EP1729814A2 (en) 2004-04-01 2006-12-13 Cardiome Pharma Corp. Pegylated ion channel modulating compounds
US8058304B2 (en) 2004-04-01 2011-11-15 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
MXPA06011419A (es) 2004-04-01 2007-04-20 Cardiome Pharma Corp Profarmacos de compuestos moduladores de canales ionicos y usos de los mismos.
EP1868598B1 (en) * 2004-11-08 2014-04-23 Cardiome Pharma Corp. A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
CA2586925C (en) 2004-11-18 2016-06-07 Cardiome Pharma Corp. Synthetic process for aminocyclohexyl ether compounds
US20090005576A1 (en) * 2005-01-12 2009-01-01 Astellas Pharma Inc. Production Method of Optically Active Cyclohexane Ether Compounds
BRPI0612138B8 (pt) 2005-06-15 2021-05-25 Cardiome Pharma Corp compostos éter aminocicloexílicos e método para fazer os mesmos
DE602006018182D1 (de) 2005-08-23 2010-12-23 Kaneka Corp Verfahren zur herstellung von aralkyloxypyrrolidinderivaten
EP1950198B1 (en) * 2005-10-31 2014-08-06 Toray Fine Chemicals Co., Ltd. Process for production of benzyloxypyrrolidine derivative, and process for production of hydrochloride salt powder of optically active benzyloxypyrrolidine derivative
JP5004073B2 (ja) * 2006-06-13 2012-08-22 東レ・ファインケミカル株式会社 光学活性ベンジルオキシピロリジン誘導体塩酸塩粉体及びその製造法
JP2007131597A (ja) * 2005-11-11 2007-05-31 Toray Fine Chemicals Co Ltd ベンジルオキシピロリジン誘導体の製造方法
JP5004067B2 (ja) * 2005-10-31 2012-08-22 東レ・ファインケミカル株式会社 ベンジルオキシ含窒素環状化合物の製造法
NZ581351A (en) * 2007-05-04 2012-07-27 Cardiome Pharma Corp Controlled release oral formulations of vernakalant hydrochloride and related methods for preventing arrhythmia
WO2012024104A2 (en) 2010-08-16 2012-02-23 Codexis, Inc. Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine
US9006460B2 (en) 2010-08-16 2015-04-14 Cardiome International Ag Process for preparing aminocyclohexyl ether compounds
EP3174935B1 (de) * 2014-08-01 2023-06-21 Covestro Intellectual Property GmbH & Co. KG Copolycarbonat-zusammensetzungen mit cyclischen und linearen oligomeren und verbesserten optischen eigenschaften

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2954380A (en) * 1958-11-26 1960-09-27 Us Vitamin Pharm Corp Piperazinocyclohexyl esters
US3218328A (en) * 1963-02-18 1965-11-16 U S Vitamin & Pharmacentical C Heterocyclic amino phenoxyacetic acids, acid addition salts and quaternary ammonium salts thereof
DE2259260A1 (de) 1972-12-04 1974-06-06 Merck Patent Gmbh Neue amine
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
US4179501A (en) * 1976-11-12 1979-12-18 The Upjohn Company Analgesic N-(2-aminocycloaliphatic)azidobenzamides
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4598087A (en) * 1983-12-06 1986-07-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
NZ212108A (en) 1984-05-18 1988-10-28 Glaxo Group Ltd Aminocyclopentyl ethers and pharmaceutical compositions
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
DE3668268D1 (de) 1985-10-25 1990-02-22 Upjohn Co Verwendung von cis-n-(2-aminocycloaliphatische) benzen acetamid und benzamid zur herstellung von antikrampfmittel.
US5059620A (en) * 1985-12-27 1991-10-22 The Du Pont Merck Pharmaceutical Company Aryl substituted aminomethyl benzene derivatives
US4855316A (en) * 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
US5051428A (en) * 1988-12-06 1991-09-24 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
AU626949B2 (en) 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US4906655A (en) 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
JPH02270864A (ja) 1989-04-12 1990-11-05 Asahi Glass Co Ltd フルオロカルバサイクリックヌクレオシドおよびその製造法
US5428031A (en) * 1991-12-03 1995-06-27 Merck & Co., Inc. Methods of treating cardiac arrhythmia
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CA2058502A1 (en) 1991-12-27 1993-06-28 David C. Horwell 2-amino-mono-methoxycyclohexyl amides useful as analgesics
EP0552386A1 (en) 1992-01-13 1993-07-28 Warner-Lambert Company 2-Amino-3 or 6-methoxycyclohexyl amide derivatives
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
HK1000684A1 (en) 1992-03-26 1998-04-17 不列颠哥伦比亚大学 Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
GB9220286D0 (en) 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
US5451596A (en) 1992-12-29 1995-09-19 Rhone Poulenc Rorer Pharmaceuticals Inc. Cycloalkyl amine bis-aryl squalene synthase inhibitors
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5492825A (en) * 1993-08-06 1996-02-20 The Regents Of The University Of California Mammalian inward rectifier potassium channel cDNA, IRK1, corresponding vectors, and transformed cells
ES2170102T3 (es) * 1993-09-24 2002-08-01 Univ British Columbia Aminociclohexilesteres y utilizacion de los mismos.
GB9406043D0 (en) * 1994-03-26 1994-05-18 Smithkline Beecham Plc Compounds
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
JPH10503768A (ja) * 1994-08-02 1998-04-07 メルク シヤープ エンド ドーム リミテツド アゼチジン、ピロリジンおよびピペリジン誘導体
WO1996009069A1 (en) * 1994-09-19 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. Novel medicinal use of 5ht3 antagonist
US5556990A (en) 1994-12-16 1996-09-17 Rhone-Poulenc Rorer Pharmaceuticals Inc. Polyarylcarbamoylaza- and -carbamoylalkanedioic acids
WO1996023894A1 (de) 1995-02-03 1996-08-08 Basf Aktiengesellschaft Racematspaltung primärer und sekundärer heteroatomsubstituierter amine durch enzym-katalysierte acylierung
SK101398A3 (en) 1996-01-25 1998-12-02 Schering Ag Improved concentrated injection and infusion solutions for intravenous administration
US5646151A (en) 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
CZ425598A3 (cs) 1996-06-27 1999-08-11 Smithkline Beecham Corporation Antagonista IL-8 receptoru
US5935945A (en) * 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6399618B1 (en) * 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
TW536401B (en) 1997-09-03 2003-06-11 Cardiome Pharma Corp A pharmaceutical composition of N,N-bis(phenylcarbamoylmethyl)dimethylammomum chloride and derivatives for the treatment of pain
MXPA00002969A (es) 1997-09-26 2002-06-21 Nortran Pharmaceuticals Inc Mezclas de enantiomeros de aminociclohexilamidas para producir analgesia simultanea con anestesia local o antiarritmia.
JP3773644B2 (ja) * 1998-01-06 2006-05-10 芝府エンジニアリング株式会社 接点材料
US6013830A (en) 1998-03-30 2000-01-11 Sepracor Inc. Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
JP4334766B2 (ja) * 1998-04-01 2009-09-30 カーディオム ファーマ コーポレイション アミノシクロヘキシルエーテル化合物およびその用途
US6624761B2 (en) * 1998-12-11 2003-09-23 Realtime Data, Llc Content independent data compression method and system
US6979685B1 (en) * 1999-02-12 2005-12-27 Cardiome Pharma Corp. Cycloalkyl amine compounds and uses thereof
WO2000047547A2 (en) 1999-02-12 2000-08-17 Nortran Pharmaceuticals Inc. Cycloalkyl amine compounds and uses thereof
AU2899400A (en) * 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
CA2268590A1 (en) * 1999-04-12 2000-10-12 Nortran Pharmaceuticals Inc. Ion channel modulating compounds and uses thereof
US6150357A (en) * 1999-05-10 2000-11-21 Merck & Co., Inc. Potassium channel agonists
CN1178911C (zh) * 2000-04-20 2004-12-08 弗·哈夫曼-拉罗切有限公司 吡咯烷与哌啶衍生物和它们用于治疗神经变性疾病的用途
CA2311483A1 (en) 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US20040049049A1 (en) * 2002-06-14 2004-03-11 Johnson Matthey Pharmaceutical Materials, Inc. Stereoselective synthesis of 1,2-disubstituted cycloalkyls
WO2004008103A2 (en) 2002-07-12 2004-01-22 Cardiome Inc. Mutations of voltage-gated potassium channels
WO2004098525A2 (en) 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
SG2010079697A (en) * 2003-05-02 2016-09-29 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
WO2005016242A2 (en) * 2003-06-04 2005-02-24 Cardiome Pharma Corp. Synthetic process for trans-aminocyclohexyl ether compounds
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) * 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20070197632A1 (en) * 2003-10-31 2007-08-23 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof

Also Published As

Publication number Publication date
CA2524323C (en) 2012-05-15
AU2003287378A1 (en) 2004-11-26
ATE325789T1 (de) 2006-06-15
PL378918A1 (pl) 2006-06-12
KR101059379B1 (ko) 2011-08-26
BR0318278A (pt) 2006-05-23
DK1560812T3 (da) 2006-09-04
EP2298735A1 (en) 2011-03-23
NO20055130D0 (no) 2005-11-02
US8163938B2 (en) 2012-04-24
PT1560812E (pt) 2006-09-29
US20070099983A1 (en) 2007-05-03
BR122018009866B8 (pt) 2021-07-27
SG2010079697A (en) 2016-09-29
AU2003287378B2 (en) 2010-12-16
BR122018009866B1 (pt) 2018-12-18
NO20055130L (no) 2005-12-01
NO334094B1 (no) 2013-12-09
NZ543921A (en) 2008-11-28
SI1560812T1 (sl) 2006-10-31
CY1105137T1 (el) 2010-03-03
EP1666459A2 (en) 2006-06-07
US7767830B2 (en) 2010-08-03
BRPI0318278B1 (pt) 2018-11-06
EP1560812A1 (en) 2005-08-10
IL171653A (en) 2013-06-27
US20070254945A1 (en) 2007-11-01
EP1560812B1 (en) 2006-05-10
EP1666459B1 (en) 2011-10-19
IL216579A (en) 2015-02-26
JP2007077162A (ja) 2007-03-29
RU2008104198A (ru) 2009-08-10
ES2375820T3 (es) 2012-03-06
AU2011201015B2 (en) 2012-02-02
JP4919661B2 (ja) 2012-04-18
DE60305200T2 (de) 2007-05-10
CA2524323A1 (en) 2004-11-18
AU2011201015A1 (en) 2011-03-31
PL227937B1 (pl) 2018-01-31
WO2004099137A1 (en) 2004-11-18
KR20060057531A (ko) 2006-05-26
EP1666459A3 (en) 2006-09-20
RU2478617C2 (ru) 2013-04-10
ATE529401T1 (de) 2011-11-15
DE60305200D1 (de) 2006-06-14
IL216579A0 (en) 2012-01-31
JP2006525227A (ja) 2006-11-09
HK1091814A1 (zh) 2007-01-26
ES2264776T3 (es) 2007-01-16
SG167670A1 (en) 2011-01-28
US20110004006A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
BRPI0318278B8 (pt) Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
TW200509983A (en) The dermal external agent for inhibiting or repairing the dermal damage due to drying
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
UA96115C2 (uk) Спосіб і композиція для лікування амілоїдогенних захворювань
TW200505458A (en) 1-amino 1h-imidazoquinolines
DK1313462T3 (da) Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer
TR200200883T2 (tr) 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
IL155263A0 (en) Pharmaceutical solutions of modafinil compounds
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
DE60008798D1 (de) Extrakt von undifferenzierten zellen einer pflanze der gattung leontopodium und ihn enthaltende zusammensetzungen
SE0003476D0 (sv) Compounds
TW200716088A (en) Formulations and methods for treating amyloidosis
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.
NO20051261L (no) Morfin-6-glukuronidsalt
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
ES2187446T3 (es) Composicion para el tratamiento de la psoriasis.
IL182298A0 (en) 4-hydroxy tamoxifen gel formulations
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
WO2005013903A3 (en) Derivatives of substituted quinone and uses thereof
BRPI0404215A (pt) processo de obtenção de antioxidante odontológico e produto obtido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 3A ANUIDADE.

B24D Patent annual fee: restoration after fee payment
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 3A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2607 DE 22/12/2020 POR TER SIDO INDEVIDA. UMA VEZ QUE A RESTAURACAO FOI CUMPRIDA EM 19/11/2020.

B25A Requested transfer of rights approved

Owner name: CORREVIO CANADA CORP. (CA)

B25A Requested transfer of rights approved

Owner name: CORREVIO INTERNATIONAL SARL (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2496 DE 06/11/2018 QUANTO AO PRAZO DE VALIDADE. RETIFICACAO (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2003, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )